Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

Detalles Bibliográficos
Autores principales: Hifumi, Toru, Isokawa, Shutaro, Otani, Norio, Ishimatsu, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422471/
https://www.ncbi.nlm.nih.gov/pubmed/32787901
http://dx.doi.org/10.1186/s13054-020-03227-4
_version_ 1783570011205402624
author Hifumi, Toru
Isokawa, Shutaro
Otani, Norio
Ishimatsu, Shinichi
author_facet Hifumi, Toru
Isokawa, Shutaro
Otani, Norio
Ishimatsu, Shinichi
author_sort Hifumi, Toru
collection PubMed
description
format Online
Article
Text
id pubmed-7422471
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74224712020-08-21 Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients Hifumi, Toru Isokawa, Shutaro Otani, Norio Ishimatsu, Shinichi Crit Care Letter BioMed Central 2020-08-12 /pmc/articles/PMC7422471/ /pubmed/32787901 http://dx.doi.org/10.1186/s13054-020-03227-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter
Hifumi, Toru
Isokawa, Shutaro
Otani, Norio
Ishimatsu, Shinichi
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
title Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
title_full Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
title_fullStr Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
title_full_unstemmed Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
title_short Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
title_sort adverse events associated with nafamostat mesylate and favipiravir treatment in covid-19 patients
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422471/
https://www.ncbi.nlm.nih.gov/pubmed/32787901
http://dx.doi.org/10.1186/s13054-020-03227-4
work_keys_str_mv AT hifumitoru adverseeventsassociatedwithnafamostatmesylateandfavipiravirtreatmentincovid19patients
AT isokawashutaro adverseeventsassociatedwithnafamostatmesylateandfavipiravirtreatmentincovid19patients
AT otaninorio adverseeventsassociatedwithnafamostatmesylateandfavipiravirtreatmentincovid19patients
AT ishimatsushinichi adverseeventsassociatedwithnafamostatmesylateandfavipiravirtreatmentincovid19patients

Ejemplares similares